

CITATION REPORT

List of articles citing

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

DOI: 10.1016/j.eururo.2005.04.006

European Urology, 2005, 48, 202-5; discussion 205-6.

Source: <https://exaly.com/paper-pdf/38256061/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
972	Neoadjuvant chemotherapy for invasive bladder cancer. 2005 , CD005246		27
971	[Clinical trials for bladder cancer in Germany]. 2005 , 44, 1435-8		
970	Systemische Therapie des fortgeschrittenen Urothelkarzinoms. 2005 , 11, 1210-1218		
969	Neoadjuvant chemotherapy in invasive bladder cancer. 2005 , 5, 993-1000		0
968	Chemotherapy practices and perspectives in invasive bladder cancer. 2006 , 6, 1473-82		2
967	Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. 2006 ,		
966	Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. 2006 , 97, 1348; author reply 1348-50		
965	REPLY. 2006 , 97, 1348-1350		
964	What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?. 2006 , 98, 487-9		11
963	Neoadjuvant chemotherapy for bladder cancer. <i>World Journal of Urology</i> , 2006 , 24, 531-42	4	24
962	[Bladder cancer--what's new]. 2006 , 45, 496-8		1
961	[Value of systemic chemotherapy in bladder cancer]. 2006 , 45, 586, 588-90, 592-3		1
960	[Noninvasive and invasive bladder cancer: diagnostics and treatment]. 2006 , 45, 873-84; quiz 885		4
959	Re: Complete Long-Term Survival Data from a Trial of Adjuvant Chemotherapy vs Control After Radical Cystectomy for Locally Advanced Bladder Cancer. <i>European Urology</i> , 2006 , 50, 616-617	10.2	
958	Systemic chemotherapy for urothelial cancer. 2006 , 5, 34-42		1
957	Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3095-100	2.2	59
956	Adjuvant chemotherapy of bladder cancer. 2006 , 17 Suppl 5, v129-32		11

955	Muscle invasive and metastatic bladder cancer. 2006 , 17 Suppl 10, x23-30	13
954	Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. 2006 , 17, 1360-9	8
953	A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. 2006 , 3, 675-9	
952	Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. 2007 , 7, 1729-36	6
951	Treatment of muscle-invasive bladder cancer. 2007 , 7, 1279-83	20
950	Emerging drugs for targeted therapy of bladder cancer. 2007 , 12, 435-48	5
949	Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?. 2007 , 3, 5-8	1
948	Neo-adjuvant and adjuvant chemotherapy in bladder cancer. 2007 , 18 Suppl 6, vi162-3	2
947	Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel. 2007 , 18, 745-7	4
946	Bladder Cancer: Epidemiology, Diagnosis, and Treatment. 2007 , 23, S3-S10	3
945	Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. 2007 , CD006157	31
944	[Urothelial tumors]. 2007 , 17, 1065-98	13
943	Defining optimal therapy for muscle invasive bladder cancer. 2007 , 177, 437-43	165
942	Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy. 2007 , 100, 1225-8	7
941	When and how to treat superficial and muscle-invasive bladder cancer. <i>European Urology</i> , 2007 , 52, 1554-1562	2
940	Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. 2007 , 34, 122-8	10
939	Multimodality bladder preservation therapy for muscle-invasive bladder tumors. 2007 , 34, 129-34	10
938	[Is there an indication for adjuvant or neoadjuvant systemic chemotherapy in bladder cancer?]. 2007 , 46, 1379-80, 1382-4	

937	Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial. 2007 , 26, 623-34		95
936	[Systemic oncological treatment of bladder cancer]. 2007 , 157, 157-61		1
935	Adjuvante und neoadjuvante Chemotherapie beim Harnblasenkarzinom. 2007 , 13, 1101-1108		
934	[Multimodal therapy for bladder sparing with high grade bladder tumors]. 2008 , 47, 838, 840-2, 844-5		5
933	Contemporary management of muscle-invasive bladder cancer. 2008 , 13, 504-9		10
932	Chimiothérapie néoadjuvante et carcinomes urothéliaux infiltrants de vessie de stade localisés Des données de la littérature à la pratique quotidienne: it's a long way to go.... 2008 , 10, 657-660		
931	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. 2008 , 113, 2471-7		188
930	Neoadjuvant gemcitabine and cisplatin: another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer. 2008 , 113, 2379-81		
929	Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. 2008 , 70, 456-63		103
928	Novel agents for muscle-invasive and advanced urothelial cancer. 2008 , 101, 937-43		9
927	Bladder preservation: optimizing radiotherapy and integrated treatment strategies. 2008 , 102, 1345-53		31
926	Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2008 , 54, 126-32	10.2	54
925	Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. <i>European Urology</i> , 2008 , 53, 720-31	10.2	123
924	Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy. <i>Urology</i> , 2008 , 72, 379-83	1.6	26
923	[Prognostic value of lymph node dissections in bladder cancer treated with radical cystectomy]. 2008 , 18, 351-7		4
922	Improving outcomes after radical cystectomy. 2008 , 180, 12-3		4
921	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. 2008 , 9, 1885-93		2
920	Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. 2008 , 47, 937-40		7

919	Management of muscle-invasive bladder cancer: an update. 2008 , 5, 501-8		18
918	Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. 2008 , 5, 484-5		10
917	The chemotherapeutic management of bladder cancer. 125-136		
916	Adjuvant and neoadjuvant therapy in renal cell carcinoma. 2008 , 14, 315-9		11
915	Vinflunine in the treatment of bladder cancer. 2008 , 4, 1243-53		10
914	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. 2009 , 9, 821-30		18
913	Organ-sparing strategies in the management of invasive bladder cancer. 2009 , 9, 1765-75		7
912	Clinical states model for biomarkers in bladder cancer. 2009 , 5, 977-92		10
911	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
910	Bladder cancer: modeling and translation. 2009 , 23, 655-9		10
909	Loss of prostatic (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT). 2009 , 9, 377		29
908	Comprehensive surgical and chemotherapy treatment for invasive bladder cancer. 2009 , 33, 1062-8		2
907	External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. <i>European Urology</i> , 2009 , 56, 113-21	10.2	16
906	Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. <i>European Urology</i> , 2009 , 55, 348-58	10.2	67
905	Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. 2009 , 115, 792-9		75
904	Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. 2009 , 115, 5193-201		7
903	Urothelial carcinoma: stem cells on the edge. 2009 , 28, 291-304		48
902	The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma. 2009 , 10, 267-74		7

901	Targeting angiogenesis in bladder cancer. 2009 , 11, 244-9		26
900	[Systemic chemotherapy for bladder cancer: news in 2009]. 2009 , 48, 655-62		
899	Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. 2009 , 104, 189-94		30
898	Neoadjuvant systemic therapy for urological malignancies. 2010 , 106, 6-22		21
897	Defining the clinical target volume for bladder cancer radiotherapy treatment planning. 2009 , 75, 1379-84		16
896	Adjuvant chemotherapy in lymph node positive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 160-4	2.8	12
895	Optimizing outcomes at every stage of bladder cancer: do we practice it?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 72-4	2.8	14
894	Bladder cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 653-67	2.8	139
893	Management of bladder cancer: current and emerging strategies. 2009 , 69, 1173-87		12
892	Harnblasenkarzinom. 2009 , 395-476		0
891	Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?. 2009 , 9, 747-52		0
890	Bladder cancer. 2009 , 374, 239-49		817
889	The effect of age on bladder cancer incidence, prognosis and therapy. 2010 , 6, 649-659		6
888	A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. 2010 , 186, 565-71		22
887	[Value of biomarkers in urology]. 2010 , 49, 547-59		1
886	[Update on chemotherapy for bladder cancer. Update 2010]. 2010 , 49, 1294-300		2
885	A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. 2010 , 77, 119-24		54
884	Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. 2010 , 37 Suppl 1, S38-44		18

883	FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. <i>European Urology</i> , 2010 , 57, 641-7	10.2	122
882	Editorial comment on: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. <i>European Urology</i> , 2010 , 57, 647	10.2	2
881	Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. <i>European Urology</i> , 2010 , 58, 105-11	10.2	24
880	Reply from Authors re: Guido Dalbagni. Prognostication of Upper Tract Urothelial Carcinoma: What Do We Really Need? <i>Eur Urol</i> 2010;57:582B. <i>European Urology</i> , 2010 , 57, 583-585	10.2	
879	Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. <i>European Urology</i> , 2010 , 58, 581-7	10.2	165
878	Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. 2010 , 116, 2967-73		140
877	The effect of age and gender on bladder cancer: a critical review of the literature. 2010 , 105, 300-8		193
876	New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. 2010 , 106, 168-79		5
875	Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). 2011 , 108, 693-9		39
874	Evidence-based clinical practice guidelines for bladder cancer (summary - JUA 2009 Edition). <i>International Journal of Urology</i> , 2010 , 17, 102-24	2.3	20
873	[Perioperative strategies in patients with muscle invasive bladder cancer]. 2010 , 97 Suppl Cancer de la vessie, 5-9		1
872	Bladder cancer. 2010 , 22, 242-9		29
871	Reply. <i>Urology</i> , 2010 , 75, 1504	1.6	0
870	Role of biomarkers to predict outcomes and response to therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 97-101	2.8	4
869	Current Value of Neoadjuvant Chemotherapy Prior to Cystectomy. 2010 , 9, 424-427		3
868	Cadherin switching and bladder cancer. 2010 , 184, 423-31		79
867	[Recommendations Onco-Urology 2010: Urothelial tumors]. 2010 , 20 Suppl 4, S255-74		25
866	Urothelial carcinoma of the bladder: definition, treatment and future efforts. 2011 , 8, 631-42		100

865	Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. 2011 , 185, 1621-6		84
864	Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. 2011 , 185, 456-61		70
863	[The role of chemotherapy in the management of bladder cancer]. 2011 , 21, 369-82		4
862	T-staging of bladder cancer - is it time to admit defeat?. 2011 , 66, 1146-7		
861	Reply by the Authors. <i>Urology</i> , 2011 , 77, 252-253	1.6	
860	Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 252-8	2.8	116
859	Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. 2011 , 10, e20-e25		2
858	Current therapeutic strategies for invasive and metastatic bladder cancer. 2011 , 4, 97-113		28
857	Update on chemotherapy in the treatment of urothelial carcinoma. 2011 , 11, 1981-94		21
856	Bladder Cancer. 2011 , 801-827		
855	Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. 2011 , 21, 420-7		33
854	Management of elderly patients with advanced infiltrating and metastatic bladder cancer: an oncogeriatric approach. 2011 , 7, 491-502		
853	Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. 2011 , 5, 57-61		
852	Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. 2011 , 107, 58-62		39
851	Induction chemotherapy for unresectable urothelial carcinoma of the bladder. 2011 , 107, 894-7		17
850	Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. 2011 , 107, 46-52		34
849	Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. 2011 , 108, 539-45		119
848	Maximizing outcomes in genitourinary cancers across the treatment continuum. 2011 , 107 Suppl 2, 1-12		1

847	Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. <i>European Urology</i> , 2011 , 59, 978-84	10.2	37
846	Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. <i>European Urology</i> , 2011 , 59, 1009-18	10.2	465
845	Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. 2011 , 117, 276-82		104
844	Erratum to: Strahlentherapie und Onkologie, volume 186 (no. 10). 2011 , 187, 267-267		0
843	[Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery?]. 2011 , 50, 706-13		8
842	Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). 2011 , 28, 1356-62		3
841	Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?. 2011 , 5, 185-189		1
840	Diagnosis and management of urothelial carcinoma of the bladder. 2011 , 123, 43-55		24
839	Role of chemotherapy in upper urinary tract urothelial cell cancers. 2011 , 7, 1067-75		
838	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. 2011 , 10, 733-42		30
837	Are we undertreating invasive bladder cancer? Optimizing outcomes in a high-risk disease. 2011 , 5, 192-8		
836	Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 733-8	2.2	123
835	Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2135-7	2.2	24
834	New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. 2011 , 17, 2608-12		79
833	International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2171-7	2.2	611
832	Joint genitourinary cancer symposium between Egyptian and American centers. 2011 , 11, 697-9		
831	Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. 2011 , 41, 908-14		25
830	Immunotherapy for urothelial carcinoma: current status and perspectives. 2011 , 3, 3055-72		23

829	Progress in personalizing chemotherapy for bladder cancer. 2012 , 2012, 364919		15
828	Urothelial cancers: using biology to improve outcomes. 2012 , 12, 87-98		5
827	Bladder cancer pharmacogenomics: recent insights and future perspectives. 2012 , 13, 1553-6		3
826	Chemotherapy for bladder cancer in patients with impaired renal function. 2011 , 9, 52-7		13
825	Perioperative chemotherapy for upper tract urothelial cancer. 2012 , 9, 266-73		17
824	The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. 2012 , 106, 1187-95		17
823	Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy. 2012 , 42, 202-7		18
822	Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) - opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial. 2012 , 110, 919-21		29
821	Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. 2012 , 461, 467-74		8
820	Development of a nomogram to predict non-organ-confined bladder urothelial cancer before radical cystectomy. 2012 , 44, 1711-9		20
819	A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 523-33	10.2	162
818	[Chemotherapy in perioperative setting for infiltrative bladder cancer]. 2012 , 22, 139-45		1
817	Novel molecular targets for the therapy of urothelial carcinoma. 2012 , 16, 499-513		1
816	Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. <i>Urology</i> , 2012 , 79, 1085-91	1.6	171
815	Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. <i>Urology</i> , 2012 , 80, 736.e1-5	1.6	10
814	[Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. 2012 , 36, 449-60		36
813	Recommendations for the optimal management of early and advanced urothelial carcinoma. 2012 , 38, 431-41		10
812	Peri-operative morbidity and mortality related to radical cystectomy: a multi-institutional retrospective study in Japan. 2012 , 110, E756-64		48

811	Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?. 2012 , 188, 358-60		2
810	Surgical and chemotherapeutic management of regional lymph nodes in bladder cancer. 2012 , 188, 1081-8		15
809	Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?. 2012 , 188, 1108-13		33
808	Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. 2012 , 4, 15-21		15
807	Lokal fortgeschrittenes Blasenkarzinom. 2012 , 18, 994-1002		
806	Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. 2012 , 36, 449-460		9
805	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. 2012 , 118, 3920-7		34
804	[Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies]. 2012 , 51, 820-8		14
803	[Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")]. 2012 , 51, 829-36		
802	Current chemotherapeutic strategies against bladder cancer. 2012 , 44, 431-41		6
801	Neoadjuvant chemotherapy for invasive bladder cancer. 2012 , 13, 136-46		16
800	Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen. <i>International Journal of Urology</i> , 2012 , 19, 26-38	2.3	5
799	Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. <i>International Journal of Urology</i> , 2012 , 19, 388-401	2.3	47
798	Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. <i>European Urology</i> , 2012 , 61, 1229-38	10.2	166
797	Words of wisdom. Re: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastin chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>European Urology</i> , 2012 , 61, 1063-4	10.2	0
796	Intensity-modulated and image-guided radiation therapy for treatment of genitourinary carcinomas in dogs. 2012 , 26, 987-95		53
795	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. 2012 , 110, 804-11		73
794	Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. 2012 , 110, 1463-70		32

793	Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. 2012 , 118, 72-81		37
792	Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach. 2012 , 118, 44-53		35
791	[When should systemic chemotherapy be used for urinary bladder carcinoma?]. 2012 , 51, 325-30		
790	Optimal Management of the Elderly Patient with Muscle-Invasive Bladder Cancer. 2013 , 2, 58-65		1
789	Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. 2013 , 13, 71		61
788	SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer. 2013 , 20, 3669-74		11
787	The role of systemic chemotherapy in management of upper tract urothelial cancer. 2013 , 14, 94-101		13
786	Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. <i>World Journal of Urology</i> , 2013 , 31, 77-82	4	17
785	Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>Urology</i> , 2013 , 82, 1386-92	1.6	33
784	Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1751-60	2.8	29
783	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 812-26	2.8	6
782	The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 407-13	2.8	58
781	Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1709-15	2.8	23
780	[Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer]. 2013 , 52, 1534-8, 1540		
779	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. <i>European Urology</i> , 2013 , 63, 58-66	10.2	133
778	Tailored Treatment for Bladder Cancer in Older Patients. 2013 , 271-279		
777	Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. 2013 , 189, 1682-6		49
776	Optimizing outcomes for octogenarians with invasive bladder cancer: One size does not fit all. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1-4	2.8	5

775	[CCAFU Recommendations 2013: Bladder carcinoma]. 2013 , 23 Suppl 2, S105-25		16
774	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. 2013 , 11, 316-20		4
773	Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience. 2013 , 39, 365-71		23
772	FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. 2013 , 189, 1687-91		39
771	Cáncer de vejiga. 2013 , 11, 1568-1577		
770	Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. 2013 , 11, 175-81		74
769	A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. <i>Urology</i> , 2013 , 82, 111-7	1.6	26
768	Current perspectives in bladder cancer management. 2013 , 67, 435-48		78
767	Delivering adaptive radiotherapy to the bladder during radical treatment. 2013 , 12, 195-202		1
766	Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. 2013 , 24, 2414-21		10
765	Actionable mutations in muscle-invasive bladder cancer. 2013 , 23, 472-8		15
764	Comparison of adaptive radiotherapy techniques for the treatment of bladder cancer. 2013 , 86, 20120433		22
763	Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. 2013 , 18, 933-40		11
762	Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. 2013 , 7, 312-8		17
761	Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system. 2013 , 7, E667-72		5
760	¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. <i>International Journal of Urology</i> , 2013 , 20, 788-96	2.3	31
759	Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer. 2013 , 9, 310-7		10
758	Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. 2013 , 9, 1637-51		14

757	Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. 2013 , 112, 729-34	57
756	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. 2013 , 112, 453-61	97
755	The treatment of muscle-invasive bladder cancer in elderly patients. 2013 , 9, 529-538	
754	Neoadjuvant chemotherapy in bladder cancer. 2013 , 3, 991-1002	2
753	Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis. 2013 , 13, 73	11
752	Role of systemic chemotherapy in urothelial urinary bladder cancer. 2013 , 20, 200-10	20
751	New therapeutic targets in the management of urothelial carcinoma of the bladder. 2013 , 5, 53-65	4
750	The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. 2013 , 4, 686-90	30
749	Optimizing care and outcomes of patients with muscle-invasive bladder cancer. 2013 , 7, E625-7	1
748	Perioperative chemotherapy for muscle-invasive bladder cancer. 2009 , 3, S223-7	7
747	Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer. 2008 , 2, 225-7	2
746	Current approaches to the management of bladder cancer in older patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e250-6	7.1 6
745	Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. 2014 , 6, 459-65	15
744	Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. 2014 , 8, 1985-90	4
743	The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. 2014 , 96, 415-9	14
742	Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. 2014 , 8, e287-93	9
741	Current Evidence for the Treatment of Bladder Cancer. 2014 , 37, 1	1
740	Uptake of neoadjuvant chemotherapy for invasive bladder cancer. 2014 , 8, e294-5	4

739	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. 2014 , 4, 1140-53	361
738	Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. 2014 , 114, 674-9	33
737	Systemische Therapie des metastasierten Urothelkarzinoms. 2014 , 20, 1133-1135	
736	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. 2014 , 14, 966	20
735	Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. 2014 , 25, 1192-8	73
734	Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer. 2014 , 6, 273-7	1
733	Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma. 2014 , 14, 543-51	4
732	T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. 2014 , 8, 486	15
731	[FRancilian Oncogeriatric Group (FROG)'s focus on management of elderly patients with bladder cancer]. 2014 , 101, 841-55	2
730	Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. 2014 , 14, 1429-43	1
729	Serum total hCG level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. 2014 , 110, 1759-66	20
728	[Pharmaceutical treatment of advanced urinary bladder cancer: new developments in 2014]. 2014 , 53, 1535-42	
727	Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. 2014 , 113, E17-21	42
726	Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. 2014 , 120, 1630-8	70
725	Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1200-8	24
724	Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. 2014 , 105, 704-12	46
723	[Concomitant chemoradiotherapy for muscle-invasive bladder cancer: current knowledge, controversies and future directions]. 2014 , 18, 779-89	0
722	ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis. 2014 , 25, 106-14	16

721	Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1868-70	2.2	10
720	Update in systemic therapy of urologic malignancies. 2014 , 126, 44-54		6
719	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. 2014 , 8, 309-16		12
718	Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. 2014 , 2014, 746298		34
717	Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. <i>European Urology</i> , 2014 , 66, 42-54	10.2	277
716	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 31.e17-24	2.8	39
715	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 47.e9-14	2.8	44
714	The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2014 , 32, 453-9	4	16
713	Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. <i>World Journal of Urology</i> , 2014 , 32, 1463-8	4	6
712	Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. <i>World Journal of Urology</i> , 2014 , 32, 1295-301	4	13
711	EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. <i>European Urology</i> , 2014 , 65, 778-92	10.2	727
710	Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. <i>European Urology</i> , 2014 , 66, 120-37	10.2	190
709	The economics of bladder cancer: costs and considerations of caring for this disease. <i>European Urology</i> , 2014 , 66, 253-62	10.2	311
708	The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 806-14	2.8	65
707	Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection. 2014 , 31, 912		9
706	Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. 2014 , 114, 67-74		33
705	The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study. <i>European Urology</i> , 2014 , 66, 561-8	10.2	52
704	Second-line chemotherapy for advanced bladder cancer: a survey of current UK practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 52.e11-7	2.8	1

703	Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse model. 2014 , 224, 128-35		11
702	Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 975-80	2.8	21
701	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. 2014 , 120, 1794-9		132
700	Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1078-87	2.8	37
699	Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. 2014 , 12, e233-40		20
698	Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. 2014 , 12, 287-91		16
697	Why is perioperative chemotherapy for bladder cancer underutilized?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 391-5	2.8	12
696	A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>European Urology</i> , 2014 , 66, 529-41	10.2	181
695	Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. 2014 , 191, 35-9		5
694	Defining the potential of neoadjuvant chemotherapy use as a quality indicator for bladder cancer care. 2014 , 192, 43-9		8
693	Pharmacogenomics in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 16-22	2.8	13
692	Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial. <i>European Urology</i> , 2014 , 65, 509-11	10.2	9
691	Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. 2014 , 191, 898-906		38
690	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1895-901	2.2	184
689	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 637-44	2.8	41
688	Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. <i>European Urology</i> , 2014 , 66, 55-6	10.2	12
687	Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. 2014 , 113, 521-6		21
686	T2 muscle-invasive bladder cancer. 2014 , 41, e11-8		

- 685 Quimioterapia perioperatoria en c ncer de vejiga: m s evidencia que realidad. **2015**, 24, 106-112
- 684 Economics of bladder cancer. **2015**, 90-102
- 683 Management of muscle-invasive bladder cancer in the elderly. **2015**, 25, 459-67 12
- 682 Emerging immunotherapies for bladder cancer. **2015**, 27, 191-200 21
- 681 Chemoradiatie bij het spierinvasieve blaascarcinoom. **2015**, 5, 210-214
- 680 External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes. **2015**, 39, 473-481 2
- 679 Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis. **2015**, 49, 387-94 28
- 678 Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data. **2015**, 34, 2881-98 28
- 677 Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer. **2015**, 116, 373-81 7
- 676 Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy. **2015**, 1, 137-142 13
- 675 Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. **2015**, 9, 236-41 7
- 674 Optimal management of muscle-invasive bladder cancer - a review. **2015**, 7, 143-51 17
- 673 The Role of Population-Based Observational Research in Bladder Cancer. **2015**, 1, 123-131 1
- 672 Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients. *Frontiers in Oncology*, **2015**, 5, 246 5.3 5
- 671 Bladder cancer in the elderly patient: challenges and solutions. **2015**, 10, 939-49 31
- 670 [EFFICACY OF NEOADJUVANT GEMCITABINE AND CISPLATIN IN THE MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER]. **2015**, 106, 1-6 2
- 669 Radioth rapie p riop ratoire dans la prise en charge des tumeurs uroth liales infiltrantes de la vessie (TVIM) : une indication  reconsid rer ?. **2015**, 17, 171-177
- 668 The Estrogen Pathway: Estrogen Receptor- Progesterone Receptor, and Estrogen Receptor-  Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. **2015**, 13, 476-84 19

667	The Efficacy of Postoperative Adjuvant Chemotherapy for Patients with pT3N0M0 Upper Tract Urothelial Carcinoma. 2015 , 194, 323-9		26
666	Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. 2015 , 42, 201-15, viii		13
665	Diagnosis of Bladder Carcinoma: A Clinician's Perspective. 2015 , 8, 677-85		14
664	Contemporary Systemic Therapy for Urologic Malignancies in Geriatric Patients. 2015 , 31, 645-65		1
663	[Diagnosis and therapy of bladder cancer]. 2015 , 157, 42-5		
662	Quimioterapia neoadyuvante con gemcitabina-cisplatino vs metotrexato-vinblastina-adriamicina-cisplatino en pacientes con carcinoma urotelial vesical llevados a cistectomía radical: metaanálisis. 2015 , 24, 89-100		
661	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 76-86	21.7	237
660	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2015 , 67, 241-9	10.2	178
659	Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. 2015 , 370, 20140042		32
658	Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?. 2015 , 45, 315-22		12
657	Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. 2015 , 11, 731-42		9
656	Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. <i>European Urology</i> , 2015 , 67, 363-75	10.2	128
655	The role of genomics in the management of advanced bladder cancer. 2015 , 16, 319		10
654	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015 , 68, 238-53	10.2	168
653	Evaluation and Management of the Geriatric Urologic Oncology Patient. 2015 , 4, 7-15		5
652	Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. 2015 , 13, 178-84		12
651	High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. 2015 , 13, e243-e251		17
650	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015 , 68, 959-67	10.2	270

649	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 204.e1-7	2.8	28
648	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. 2015 , 41, 699-706		12
647	Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. 2015 , 112, 1626-35		20
646	Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. 2015 , 49, 453-462		10
645	Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice. 2015 , 42, 181-7, viii		7
644	Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. 2015 , 141, 169-76		13
643	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. 2015 , 15, 15		1
642	Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. 2015 , 84, 1023-8		18
641	Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 387-96	7	62
640	Perioperative therapy for muscle invasive bladder cancer. 2015 , 29, 301-18, ix		2
639	Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. <i>International Journal of Urology</i> , 2015 , 22, 163-70	2.3	9
638	Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy. 2015 , 45, 963-7		1
637	Muscle-invasive urothelial bladder cancer: an update on systemic therapy. 2015 , 7, 312-30		31
636	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 386.e1-6	2.8	11
635	External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes. 2015 , 39, 473-81		3
634	A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy. <i>European Urology</i> , 2015 , 68, 742-3	10.2	4
633	[The role of chemotherapy in bladder cancer]. 2015 , 25, 907-11		1
632	The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. 2015 , 193, 1494-9		10

631	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 36-49	7	15
630	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. 2016 , 10, E82-6		17
629	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. 2016 , 2, 263-272		6
628	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. 2016 , 5, 735-744		31
627	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. 2016 , 5, 702-710		11
626	Targeting XBP1-mediated IκBα expression associated with bladder cancer with newly synthetic Oridonin analogues. 2016 , 7, 56842-56854		20
625	Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis. 2016 , 4, 636-642		5
624	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. 2016 , 6,		33
623	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. 2016 , 14, 1213-1224		73
622	SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). 2016 , 18, 1197-1205		8
621	Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. 2016 , 16, 578		57
620	The role of chemotherapy and new targeted agents in the management of primary prostate cancer. 2016 , 9, 30-37		2
619	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. 2016 , 5, e1134412		94
618	Viscoelastic properties of human bladder tumours. 2016 , 61, 250-257		26
617	Building the Case for Adjuvant Chemotherapy After Radical Cystectomy: Commentary on: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Urology</i> , 2016 , 94, 1-2	1.6	3
616	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. 2016 , 21, 708-15		183
615	Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 418.e9-418.e16	2.8	11
614	Urothelial carcinoma management in elderly or unfit patients. 2016 , 14, 1-20		34

613	Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. 2016 , 46, 468-74		2
612	Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 1567-1573	4	16
611	Design of an improved surgical instrument for the removal of bladder tumours. 2016 , 230, 579-87		1
610	Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. <i>Urology</i> , 2016 , 95, 132-8	1.6	17
609	Adjuvant Chemotherapy Is More Suitable Than Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Patients Treated With Radical Chemoradiotherapy. 2016 , 96, 614-6		3
608	Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy. 2016 , 23, 1048-1054		56
607	Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Oncology</i> , 2016 , 28, 790-796	2.8	14
606	Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. 2016 , 5, 1098-107		4
605	Bladder Preservation for Muscle Invasive Bladder Cancer. 2016 , 2, 151-163		18
604	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. 2016 , 196, 1627-1633		26
603	A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy. 2016 , 5, 1167		7
602	Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. 2016 , 6, 35854		12
601	Emerging role of checkpoint inhibition in localized bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 548-555	2.8	14
600	Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. 2016 , 69, 1-8		26
599	Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer. 2016 , 2, 351-360		22
598	Upper tract urothelial carcinoma: a different disease entity in terms of management. 2016 , 1, e000126		36
597	The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2016 , 34, 1561-1566	4	3
596	Treatment of elderly patients with advanced urological cancer. 2016 , 9, 20-29		

595	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. 2016 , 12, 2049-58		5
594	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 469-76	2.8	7
593	Bladder cancer. 2016 , 388, 2796-2810		669
592	Molecular substratification of bladder cancer: moving towards individualized patient management. 2016 , 8, 215-33		27
591	Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2627-35	2.2	52
590	Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. 2016 , 12, 1795-804		6
589	Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. <i>Journal of Clinical Oncology</i> , 2016 , 34, 777-9	2.2	3
588	Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 780-5	2.2	6
587	Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 825-32	2.2	116
586	[Update 2016 - Immunotherapy for urothelial carcinoma]. 2016 , 55, 246-52		
585	Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. 2016 , 14, e59-65		31
584	Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. 2016 , 43, 77-86		8
583	Improving Systemic Chemotherapy for Bladder Cancer. 2016 , 18, 27		30
582	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 37-46	7	152
581	The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. 2016 , 22, 2323-8		14
580	Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands. 2016 , 54, 18-26		33
579	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 4.e11-7	2.8	9
578	Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. 2016 , 14, 82-8		24

577	Chemotherapy for Muscle-Invasive Bladder Cancer. 2016 , 17, 6		8
576	Bladder cancer. 2016 , 44, 52-55		2
575	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. 2016 , 14, 352-9		21
574	Neoadjuvant chemotherapy-related histologic changes in radical cystectomy: assessment accuracy and prediction of response. 2016 , 53, 35-40		10
573	Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. 2016 , 54, 69-74		11
572	Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 19-24	4	19
571	Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. <i>World Journal of Urology</i> , 2016 , 34, 3-11	4	16
570	Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis. 2016 , 22, 1086-94		14
569	Bladder Cancer. 2016 , 1096-1120.e6		0
568	External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. 2016 , 195, 283-9		13
567	An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer. 2016 , 14, e67-74		1
566	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016 , 34, 695-701	4	1
565	Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. <i>World Journal of Urology</i> , 2016 , 34, 157-62	4	33
564	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. 2016 , 195, 53-9		72
563	Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer. 2017 , 15, 145-151.e2		28
562	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017 , 71, 462-475	10.2	924
561	Impact of neoadjuvant chemotherapy on complications of minimally invasive radical cystectomy. 2017 , 41, 88-96		1
560	Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy. 2017 , 15, 479-486		4

559	Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. 2017 , 176, 63-70		19
558	Robotic assisted laparoscopic radical cystectomy with stentless intracorporeal modified Ves.Pa neobladder: early experience. 2017 , 11, 423-431		2
557	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017 , 35, 1401-1407	4	26
556	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. 2017 , 54, 1-9		26
555	Metastatic Bladder Cancer. 2017 , 177-198		1
554	Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. 2017 , 15, e493-e495		1
553	[Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?]. 2017 , 21, 67-72		1
552	Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. 2017 , 15, e583-e589		5
551	The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?. <i>Clinical Oncology</i> , 2017 , 29, 344-347	2.8	4
550	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. 2016 , 1, e000123		3
549	Bladder cancer. 2017 , 3, 17022		360
548	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. 2017 , 198, 817-823		21
547	Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. 2017 , 120, 639-650		68
546	Preoperative determinant of early postoperative renal function following radical cystectomy and intestinal urinary diversion. 2017 , 49, 233-238		6
545	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017 , 35, 1729-1736	4	7
544	Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. <i>European Urology</i> , 2017 , 72, 660-664	10.2	51
543	Impact of neoadjuvant chemotherapy on complications of minimally invasive radical cystectomy. 2017 , 41, 88-96		
542	Contemporary update on neoadjuvant therapy for bladder cancer. 2017 , 14, 348-358		18

541	Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis. 2017 , 39, 1113-1121		10
540	A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 38.e9-38.e15	2.8	8
539	Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. 2017 , 97, 1002-1020		61
538	Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy. 2017 , 34, 187		5
537	A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. 2017 , 37, 1391-1405		11
536	Atezolizumab in invasive and metastatic urothelial carcinoma. 2017 , 10, 1295-1301		8
535	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. 2017 , 123, 4346-4355		85
534	Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. 2017 , 123, 3855		2
533	Cáncer de vejiga. 2017 , 12, 1955-1965		
532	Perioperatieve behandelingen en radicale cystectomie voor blaaskanker. Een trendanalyse over 10.338 patiënten in Nederland. 2017 , 7, 87-100		
531	Urothelial cancer proteomics provides both prognostic and functional information. 2017 , 7, 15819		12
530	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 120, 120-126	7	14
529	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. 2017 , 92, 1564-1582		18
528	Landmarks in the treatment of muscle-invasive bladder cancer. 2017 , 14, 565-574		65
527	Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 606.e9-606.e16	2.8	21
526	Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. 2017 , 17, 308		7
525	Epidemiology of Bladder Cancer. 2017 , 511-522		2
524	Urothelial Tumors. 2017 , 59-93		

523	Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. <i>World Journal of Urology</i> , 2017 , 35, 921-927	4	10
522	Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study. 2017 , 119, 605-611		11
521	Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. <i>World Journal of Urology</i> , 2017 , 35, 1055-1061	4	16
520	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. 2017 , 119, 684-691		24
519	Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. 2017 , 123, 794-801		36
518	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. <i>European Urology</i> , 2017 , 71, 237-246	10.2	41
517	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. 2017 , 15, 356-362		22
516	Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer. 2017 , 97, 732-739		16
515	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. 2017 , 14, 221-234		66
514	Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 34.e17-34.e25	2.8	16
513	Neoadjuvant Platinum-Based Chemotherapy is an Independent Predictor for Preoperative Thromboembolic Events in Bladder Cancer Patients Undergoing Radical Cystectomy. 2017 , 10, 132-135		2
512	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. 2017 , 6, 1067-1080		13
511	Cost of illness of urothelial bladder cancer in Italy. 2017 , 9, 433-442		9
510	Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer. <i>PLoS ONE</i> , 2017 , 12, e0184841	3.7	15
509	Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future. 2017 , 84, 130-141		7
508	Pathology review impacts clinical management of patients with T1T2 bladder cancer. 2017 , 11, 188-193		5
507	DNA Repair Pathway Alterations in Bladder Cancer. 2017 , 9,		26
506	Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study. 2017 , 8, 86130-86142		22

505	Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour. 2018 , 12, E182-E190		1
504	Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF- κ B signal-dependent and signal-independent manner. 2017 , 51, 1219-1226		10
503	Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. 2017 , 1, 1-12		2
502	Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials. 2017 , 8, 81204-81214		15
501	Novel biomarkers in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 115-119	2.8	4
500	Choline-phosphate cytidyltransferase is a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder. 2018 , 52, 200-205		3
499	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. 2018 , 122, 434-440		7
498	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. 2018 , 122, 89-98		9
497	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 405-412	2.8	30
496	Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. 2018 , 4, 31-40		8
495	Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 308.e19-308.e25	2.8	13
494	Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. 2018 , 20, 48		29
493	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. 2018 , 45, 287-295		8
492	Bladder Cancer and Other Urothelial Sites. 2018 , 237-250		
491	Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. 2018 , 200, 68-73		34
490	Risk Factors and Molecular Features Associated with Bladder Cancer Development. 2018 , 3-28		1
489	Nivolumab for the treatment of urothelial cancers. 2018 , 18, 215-221		14
488	Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study. 2018 , 16, e669-e675		7

487	Perioperative Chemotherapie des Harnblasenkarzinoms. 2018 , 24, 48-54		
486	Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. 2018 , 199, 1452-1458		45
485	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. 2018 , 85-101		
484	SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. 2018 , 19, 216		6
483	History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy. 2018 , 16, e969-e976		8
482	Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database. 2018 , 200, 535-540		2
481	Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. 2018 , 45, 155-167		11
480	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. 2018 , 4, 1-7		4
479	Magnetic Resonance Imaging Evaluation of Urothelial Cell Carcinoma: Histopathological Correlation, Staging, and Treatment Planning. 2018 , 47, 28-41		
478	Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. <i>Urology</i> , 2018 , 111, 116-121	1.6	20
477	Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. 2018 , 199, 416-423		27
476	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. 2018 , 15, 92-111		84
475	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 413-422	2.8	16
474	Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. 2018 , 9, 18797-18810		6
473	[OUTCOME OF BLADDER PRESERVATION USING LOW DOSE CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY INVASIVE BLADDER CANCER]. 2018 , 109, 59-67		1
472	Perioperative Therapieoptionen beim Harnblasenkarzinom. 2018 , 22, 32-37		
471	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49 parallel. 2019 , 13, 29-31		6
470	Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. 2018 , 7, 504-507		3

- 469 The long perspective in emergence of neoadjuvant chemotherapy for bladder cancer in Ontario, Canada-space for improvement with regular and organized multidisciplinary team meetings. **2018**, 7, 508-510 4
- 468 Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer. **2018**, 9, 24457-24469 17
- 467 Urothelkarzinom der Harnblase: Aktuelles zur Systemtherapie. **2018**, 21, 46-54
- 466 Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. *European Urology Oncology*, **2018**, 1, 525-530 6.7 16
- 465 Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis. **2018**, 19, 11
- 464 Molecular Characterization of Bladder Cancer. **2018**, 19, 107 7
- 463 Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. *Frontiers in Oncology*, **2018**, 8, 463 5.3 17
- 462 Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience. **2018**, 5, 58 7
- 461 The latest treatment options for bladder cancer. **2018**, 128, 85-95 17
- 460 Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care. **2018**, 19, 100 2
- 459 Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. **2018**, 11, 877-891
- 458 Molecular Prognostication in Bladder Cancer. **2018**, 175, 165-191 3
- 457 Advances in risk stratification of bladder cancer to guide personalized medicine. **2018**, 7, 15
- 456 Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. **2018**, 19, 47
- 455 Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. **2018**, 4, 1535-1542 59
- 454 Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. **2018**, 48, 934-941 6
- 453 Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. **2018**, 337-352
- 452 Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy. **2018**, 35, 198-203 18

451	Development and Validation of an MRI-Based Radiomics Signature for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. 2018 , 34, 76-84		75
450	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. 2018 , 70, 88-97		14
449	The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. 2018 , 9, 861-871		33
448	Neoadjuvant vs. Adjuvant Chemotherapy: Which Is Right?. 2018 , 75-81		
447	Treatment of muscle-invasive bladder cancer. 2018 , 367-372		
446	Novel therapies in urothelial carcinoma: a biomarker-driven approach. 2018 , 29, 2302-2312		4
445	Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis. 2018 , 12, 351-360		5
444	FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients. 2018 , 16, 360-364		23
443	Radical treatment of muscle-invasive bladder cancer—are options equal?. 2018 , 7, 181-186		
442	Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. <i>World Journal of Urology</i> , 2018 , 36, 1825-1833	4	2
441	Diagnostik und Therapie des Harnblasenkarzinoms. 2018 , 15, 9-20		
440	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). <i>European Urology</i> , 2018 , 74, 294-306	10.2	176
439	The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. 2018 , 4, 185-194		15
438	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. 2018 , 68, 80-85		18
437	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018 , 36, 1767-1774	4	9
436	Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer. 2018 , 8, 8360		14
435	Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. 2019 , 42, 36-41		23
434	Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade. 2019 , 6, 222-229		15

433	Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data. 2019 , 123, 818-825		6
432	Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?. 2019 , 8, S283-S286		
431	The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer. 2019 , 8, S337-S340		1
430	Local Treatment, Radical Cystectomy, and Urinary Diversion. 2019 , 351-371		
429	Peri-operative Chemotherapy for Muscle-Invasive Bladder Cancer. 2019 , 383-401		
428	Risk Stratification and Prognostication of Bladder Cancer. 2019 , 423-436		
427	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 758-764	2.8	12
426	Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. 2019 , 5, 426-439		26
425	Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer. <i>International Journal of Urology</i> , 2019 , 26, 1033-1042	2.3	12
424	Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019 , 2, 497-504	6.7	15
423	Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. 2019 , 8, 6258-6271		4
422	Neoadjuvant therapy in urothelial cancer. 2019 , 12, 329-333		0
421	Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. 2019 , 8, e1644108		14
420	Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: A meta-analysis. <i>PLoS ONE</i> , 2019 , 14, e0222223	3.7	4
419	Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy. 2019 , 19, 10		21
418	Radical Cystectomy. 2019 , 69-113		
417	The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). 2019 , 14, 15-32		5
416	The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 353.e17-353.e24	2.8	11

415	Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer. 2019 , 124, 290-296		2
414	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 61-83	4	31
413	Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy. 2019 , 24, 706-711		13
412	Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma. 2019 , 11, 4519-4528		6
411	Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: A propensity score-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 800-807 ^{2,8}		3
410	Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. 2019 , 72, 550-553		2
409	Evaluation of pro- and anti-tumor effects induced by three colony-stimulating factors, G-CSF, GM-CSF and M-CSF, in bladder cancer cells: Is G-CSF a friend of bladder cancer cells?. 2019 , 54, 2237-2249		5
408	High postoperative neutrophil-to-lymphocyte ratio as a poor prognostic marker in patients with upper tract urothelial carcinoma. 2019 , 17, 5241-5250		4
407	Radiotherapy Management of Muscle Invasive Bladder Cancer: Evaluation of a National Cohort. <i>Clinical Oncology</i> , 2019 , 31, 637-645	2.8	11
406	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. 2019 , 53, 206-212		4
405	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. 2019 , 16, 511-522		22
404	Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry. 2019 , 17, e759-e767		7
403	Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 462-469	2.8	9
402	Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy. 2019 , 53, 123-128		
401	Delays in radical cystectomy for muscle-invasive bladder cancer. 2019 , 125, 2011-2017		29
400	Bladder Neoplasm. 2019 , 409-446		
399	Systematic Review: Targeting HER2 in Bladder Cancer. 2019 , 5, 1-12		22
398	Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. 2019 , 60, 64-74		9

397	Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?. 2019 , 53, 45-50		3
396	Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. 2019 , 17, 216-222.e5		12
395	Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. <i>World Journal of Urology</i> , 2019 , 37, 2401-2407	4	2
394	Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience. <i>World Journal of Urology</i> , 2019 , 37, 2409-2418	4	4
393	Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. 2019 , 11, 1756287218823678		6
392	Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 135, 59-65	7	3 ¹
391	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. 2019 , 45, 1253-1259		4
390	Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. 2019 , 20,		15
389	The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. 2019 , 24, 580-583		
388	Capturing recurrence in urothelial carcinoma: "more than meets the eye". 2019 , 8, S524-S527		
387	Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. <i>European Urology Oncology</i> , 2019 , 2, 390-396	6.7	23
386	Advancements in the clinical management of upper tract urothelial carcinoma. 2019 , 19, 1051-1060		4
385	Imaging in Localized Bladder Cancer: Can Current Diagnostic Modalities Provide Accurate Local Tumor Staging?. 2019 , 20, 82		6
384	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. 2019 , 43, 1600-1610		15
383	Management of nonmetastatic muscle invasive bladder cancer in the elderly. 2019 , 12, 315-318		0
382	Perioperative systemic therapy for bladder cancer. 2019 , 29, 220-226		4
381	Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. 2019 , 144, 1453-1459		12
380	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018). 2019 , 21, 64-74		10

379	Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. 2019 , 247, 563-573		41
378	Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. 2019 , 5, 318-325		64
377	Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. 2019 , 123, 1011-1019		19
376	Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer. 2019 , 17, e420-e428		3
375	A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease. <i>World Journal of Urology</i> , 2019 , 37, 1605-1613	4	2
374	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. <i>World Journal of Urology</i> , 2019 , 37, 1857-1866	4	15
373	A delay 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 116-122	2.8	13
372	Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells. 2019 , 120, 6347-6360		9
371	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. 2019 , 17, 38-45		18
370	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. 2019 , 5, 849-852		0
369	Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. 2020 , 26, 330-337		2
368	Long-term oncologic outcomes of robot-assisted radical cystectomy (RARC) with totally intracorporeal urinary diversion (ICUD): a multi-center study. <i>World Journal of Urology</i> , 2020 , 38, 837-843 ⁴		23
367	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020 , 3, 671-679	6.7	7
366	PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: and Abscopal Effects. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 211-220	6.1	19
365	Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study. 2020 , 50, 73-79		6
364	Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 7.e9-7.e18 ^{2,8}		3
363	Granulocytic myeloid-derived suppressor cells correlate with outcomes undergoing neoadjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 5.e17-5.e23 ¹		1
362	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. 2020 , 18, 35-44.e1		2

361	Timing of adjuvant chemotherapy and overall survival following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 75.e15-75.e22	2.8	3
360	Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). 2020 , 20, 8		10
359	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. 2020 , 16, 4359-4368		31
358	Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. 2020 , 190, 442-452		3
357	Current applications and challenges of radiomics in urothelial cancer. 2020 , 2, 56-62		1
356	The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation. 2020 , 52, 661-669		3
355	Perioperative chemotherapy in the management of high risk upper tract urothelial cancers. 2020 , 9, 1881-1890		0
354	Risk factors and nomogram for newly diagnosis of bone metastasis in bladder cancer: A SEER-based study. 2020 , 99, e22675		3
353	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. 2020 , 26, 1839-1844		88
352	Preoperative Risk Classification Using Neutrophil-to-Lymphocyte Ratio and Albumin for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. 2020 , 12, 9023-9032		3
351	Radiomics nomogram for preoperative prediction of progression-free survival using diffusion-weighted imaging in patients with muscle-invasive bladder cancer. 2020 , 131, 109219		4
350	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma high-risk group. 2020 , 24, 212-217		3
349	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 736.e11-736.e18	2.8	2
348	Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. 2020 , 107, eS8-eS15		4
347	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 934.e1-934.e9	2.8	0
346	Systemic therapy in bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 ,	2.8	1
345	Treatment of muscle-invasive and advanced bladder cancer in 2020. 2020 , 70, 404-423		147
344	Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. 2020 , 4,		2

343	Computerized tomography before the final treatment cycle of neoadjuvant chemotherapy or induction chemotherapy in muscle-invasive urinary bladder cancer, cannot predict pathoanatomical outcomes and does not reflect prognosis-results of a single centre retrospective prognostic study. 2020, 9, 1062-1072			1
342	An overview on precision therapy in bladder cancer. 2020, 5, 347-361			
341	Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study. 2020, 50, 1464-1469			1
340	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. 2020, 6, 265-276			1
339	Considerations about Non-Metastatic Bladder Cancer Management During the COVID-19 Pandemic. 2020, 6, 99-106			1
338	Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer. 2020, 8, 51			2
337	Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience. 2020, 25, 100222			
336	Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. <i>Urology</i> , 2020, 146, 168-176	1.6		1
335	Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. 2020, 10, 15822			5
334	Precision oncology in urothelial cancer. 2020, 5, e000616			0
333	Immunotherapy for urothelial carcinoma: Metastatic disease and beyond. 2020, 16 Suppl 3, 18-23			2
332	Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020,	2.8		1
331	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic - Rapid Review. <i>Clinical Oncology</i> , 2020, 32, 347-353	2.8		6
330	Impact of neoadjuvant chemotherapy on survival prognosis and pathological downstaging in patients presenting with high-risk upper tract urothelial carcinoma: A protocol for systematic review and meta analysis. 2020, 99, e20184			4
329	Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. 2020, 12,			36
328	[Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer]. 2020, 59, 790-796			
327	Prognostic significance of non-urothelial carcinoma of bladder: analysis of nationwide hospital-based cancer registry data in Japan. 2020, 50, 1068-1075			0
326	Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery?. <i>European Urology Oncology</i> , 2020, 3, 316-317	6.7		2

325	Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. <i>Urology</i> , 2020 , 142, 155-160	1.6	5
324	Genitourinary cancer management during a severe pandemic: Utility of rapid communication tools and evidence-based guidelines. 2020 , 1, 45-59		3
323	Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2020 , 3, 544-547	6.7	21
322	Perioperative therapies for urological cancers. 2020 , 50, 357-367		1
321	Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. 2020 , 9,		5
320	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. 2020 , 6, 363-392		0
319	Antibody-drug conjugates for the treatment of urothelial carcinoma. 2021 , 21, 915-922		1
318	Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression. 2020 , 9,		5
317	Urothelial phase CT for assessment of pathologic complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer. 2020 , 126, 108902		1
316	Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. 2020 , 54, 46-51		2
315	Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. 2020 , 6, 632-638		17
314	Bladder cancer. 2020 , 48, 123-127		1
313	Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 231-239	2.8	1
312	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. 2020 , 22, 14		10
311	Bladder cancer genomics. 2020 , 87, 49-56		8
310	Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study. 2020 , 17, e1003019		30
309	Prognosis of patients receiving induction chemotherapy for locally advanced or lymph node metastatic bladder cancer. 2020 , 13, 425-436		0
308	Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities. 2020 , 18, e557-e562		4

307	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. 2020 , 18, 387-394		14
306	Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?. 2021 , 19, 47-52		0
305	Treatment Allocation and Survival in Patients Diagnosed with Nonmetastatic Muscle-invasive Bladder Cancer: An Analysis of a National Patient Cohort in England. 2021 , 7, 359-365		10
304	Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021 , 4, 204-214	6.7	8
303	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020 ;77:249-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic, Immunohistochemical, and Molecular Features. <i>European Urology</i> , 2021 , 79, 214-221	10.2	
302	Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. <i>European Urology</i> , 2021 , 79, 635-654	10.2	29
301	"Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 76.e15-76.e22	2.8	1
300	Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy. <i>Clinical Oncology</i> , 2021 , 33, 46-49	2.8	3
299	Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. <i>European Urology</i> , 2021 , 79, 214-221	10.2	44
298	Unifying Themes in Urothelial Cancers. <i>European Urology</i> , 2021 , 79, 80-81	10.2	
297	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021 , 79, 307-315	10.2	9
296	Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 299.e7-299.e14	2.8	1
295	Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer. 2021 , 51, 287-295		1
294	Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review. 2021 , 35, 453-459		1
293	Surgical Treatment in Urinary Bladder Cancer. 2021 , 189-198		
292	Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis. 2021 , 18, 505-510		1
291	Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. 2021 , 205, 100-108		2
290	Risk Stratification of Patients: Risk Tables and Assessment [NMIBC and MIBC. 2021 , 41-52		0

289	A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer. 2021 , 21, 45			9
288	Perioperative therapy in muscle invasive bladder cancer. 2021 , 37, 226-233			0
287	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. 2021 , 18, 104-114			16
286	Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. 2021 , 10, 1888-1898			3
285	DPPG-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment. 2021 , 38, 1415-1424			1
284	[Systemic treatment of bladder cancer]. 2021 , 60, 247-258			0
283	Status of Metastatic Bladder Cancer Treatment Illustrated by a Case. 2021 , 37, 1511-113			0
282	MR-Guided Adaptive Radiotherapy for Bladder Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 637591	5.3		10
281	Surgical Management of Muscle Invasive Bladder Cancer: A Review of Current Recommendations. 2021 , 37, 1511-104			0
280	Cáncer de vejiga. 2021 , 13, 1441-1453			
279	Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. 2021 , 93, 1021-142			8
278	Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer. 2021 , 11, 4842			0
277	Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort. <i>International Journal of Urology</i> , 2021 , 28, 656-664	2.3		1
276	[Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer]. 2021 , 31, 158-168			1
275	Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer. 2021 , 10, 2636-2644			1
274	The Diagnosis and Treatment of Patients With Bladder Carcinoma. 2020 , 118,			3
273	Understanding the Barriers to Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer: A Quality Improvement Initiative. 2021 , 8, 217-225			0
272	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021 , 149, 154-160	1.6		1

271	NPEPPS regulates intracellular import and sensitivity to cisplatin by interaction with volume regulated anion channels.		0
270	Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Bliemer and Arne Grønb. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer. 2021 , 23, 36		1
269	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. 2021 ,		7
268	Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer. 2021 , 60, 794-802		0
267	Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience. 2021 , 10,		3
266	Optimizing the diagnosis and management of ductal prostate cancer. 2021 , 18, 337-358		4
265	Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction. 2021 ,		
264	Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 787.e9-787.e15	2.8	2
263	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly An International Multicenter Study. 2021 , 7, 173-185		
262	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. 2021 , 128, 607-614		2
261	Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes.		1
260	Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. 2021 , 73, 215-224		2
259	Atlantis exploration: predictive biomarkers to immunotherapy response. 2021 , 17, 167-177		0
258	The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis. 2021 , 73, 144-153		6
257	Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin. 2021 , 13,		1
256	Development and Validation of a Prognostic Model for Predicting Overall Survival in Patients With Bladder Cancer: A SEER-Based Study. <i>Frontiers in Oncology</i> , 2021 , 11, 692728	5.3	2
255	Current Perioperative Therapy for Muscle Invasive Bladder Cancer. 2021 , 35, 495-511		1
254	Overcoming the Chasm Between Evidence and Routine Practice for Bladder Cancer; Just a Quixotic Notion?. <i>Clinical Oncology</i> , 2021 , 33, e274-e284	2.8	0

253	Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery?. <i>Clinical Oncology</i> , 2021 , 33, e264-e273	2.8	0
252	Muscle-invasive Bladder Cancer in the Elderly Patient With a Focus on Hypofractionated Radiotherapy. <i>Clinical Oncology</i> , 2021 , 33, 369-375	2.8	0
251	Developing Precision Medicine for Bladder Cancer. 2021 , 35, 633-653		1
250	Instant Oncology: The BC2001/BCON Meta-Analysis. <i>Clinical Oncology</i> , 2021 , 33, 745-746	2.8	
249	Molecular Classification of Bladder Cancer.		
248	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer Models. 2021 , 9, 690358		2
247	Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 435.e17-435.e22	2.8	0
246	Neoadjuvant Chemotherapy Followed by Cystectomy: a Single-Center Experience. 1		
245	A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer. 2021 ,		
244	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. 2021 , 22,		2
243	A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. 2021 , 17, 3987-3994		2
242	Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. 2021 , 57,		5
241	Clinical Characteristics, Treatment Delivery, and Cisplatin Eligibility in Korean Patients Initially Diagnosed with Urothelial Carcinoma. 2021 , 44, 63-69		
240	Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy-Phase 2 Trial Secondary Analysis.. 2022 , 8, 1-10		1
239	Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. 2021 , 13,		1
238	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. 2021 , 7, FSO709		8
237	Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer. 2021 , 30, 34-36		1
236	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 496.e9-496.e15 ^{2.8}	2.8	1

235	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. 2021 , 18, e1003732		5
234	Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients. 2021 , 47, 803-818		0
233	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). 2021 , 110, 1407-1415		4
232	A Single-arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder. 2021 , 19, 325-332		2
231	Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence. <i>Urology</i> , 2021 , 154, 8-15	1.6	2
230	Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma. 2021 , 22,		2
229	Hypofractionation: less is more?. 2021 , 12, 1729-1733		
228	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021 , 39, 4345-4354	4	2
227	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. 2021 , 13,		8
226	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. 2021 ,		2
225	Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer has no value for treatment decisions and low correlation with nodal status. 2021 , 55, 455-460		1
224	Combination of biomarkers for neoadjuvant systemic chemotherapy before cystectomy in patients with urinary bladder cancer. 2021 , 235, 77-84		1
223	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. 2021 ,		1
222	A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer. 2021 ,		0
221	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. 2021 , 2, 100382		1
220	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 528-547	2.8	
219	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3140-3148	2.2	13
218	A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer. 2021 , 31, 1-7		1

217	The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. 2021 , 13,		6
216	Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review. 2021 , 10, 4014-4021		1
215	Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man's Trash Is Another Man's Treasure. 2021 , 13,		1
214	Molecular epidemiology of DNA repair genes in bladder cancer. 2009 , 472, 281-306		8
213	Economics of Bladder Cancer Diagnosis and Surveillance. 2011 , 121-137		1
212	Current Landscape of Immunotherapy in Genitourinary Malignancies. 2020 , 1244, 107-147		2
211	Harnblasenkarzinom. 2014 , 415-502		2
210	Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions. 2020 , 6, 627-629		3
209	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. 2020 , 47, e17-e54		5
208	[French ccAFU guidelines - update 2020-2022: bladder cancer]. 2020 , 30, S78-S135		7
207	New discoveries in the molecular landscape of bladder cancer. 2016 , 5, 2875		5
206	A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. 2011 , 3, RRN1248		11
205	CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2014 , 9, e94471	3.7	6
204	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. <i>PLoS ONE</i> , 2015 , 10, e0124711	3.7	15
203	Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. 2020 , 46, 169-184		17
202	RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation. 2016 , 7, 69159-69172		13
201	Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. 2017 , 8, 722-741		15
200	miR-708-5p: a microRNA with emerging roles in cancer. 2017 , 8, 71292-71316		32

199	Optimal timing of chemotherapy and cystectomy. 2010 , 2,	1
198	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. 2015 , 4, 273-82	4
197	Saudi Oncology Society clinical management guidelines for urinary bladder cancer. 2011 , 3 Suppl, S6-9	1
196	Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?. 2017 , 33, 111-117	4
195	Systemic therapy in bladder cancer. 2017 , 33, 118-126	6
194	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017. 2018 , 10, 133-137	2
193	Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. 2020 , 61, 390-396	4
192	Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. 2016 , 48, 1084-91	13
191	Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer. 2020 , 73, 26-32	2
190	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. 2016 , 10, 25-30	15
189	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. 2016 , 10, E46-80	39
188	[Comment to "Administration de chimiothérapie néoadjuvante pour tumeur de vessie infiltrant le muscle en vie réelle: les urologues encore trop frileux?" M. Such, A. Lavoie, M.B. Popelin, C. Thibault, E. Fontaine, C. Dariane, S. Oudard, A. Mejean, M.O. Timsit, F. Audenet. Progrès en Urologie (2021) 31, 222-227, 2021, 22-23	
187	Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. 2021 , 1-13	0
186	Bladder Cancer.	
185	Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. 2007 , 33, 840-1	
184	Neoadjuvant Chemotherapy: The New Standard. 2009 , 231-237	
183	Therapieschemata in der Uroonkologie. 2009 , 1-15	
182	Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI. 2009 , 67-77	

- 181 Cancer of the Bladder. **2010**, 901-924
- 180 Tumorerkrankungen und medikamentöse Therapie. **2010**, 3-25
- 179 Neoadjuvant Chemotherapy. **2011**, 377-386
- 178 Chemotherapeutic Agents for Urologic Oncology. **2011**, 175-186 0
- 177 Cancer de la vessie/uretère. **2011**, 485-494
- 176 Urothelzelcarcinom. **2011**, 101-111
- 175 Bladder Cancer. **2011**, 511-525
- 174 Urothelial Carcinoma: Role of Perioperative Systemic Chemotherapy. **2012**, 283-292
- 173 Bladder Cancer Overview and Staging. **2012**, 83-112
- 172 Bladder Cancer. **2012**, 325-354
- 171 Management of Metastatic and Invasive Bladder Cancer. **2012**, 2355-2374.e6
- 170 Bladder Cancer. **2012**, 1099-1123 2
- 169 Health Status Evaluation of Elderly Patients with Genitourinary Tumors. **2013**, 19-38
- 168 Urologic Oncology. **2013**, 95-123
- 167 B. **2013**, 142-196
- 166 Principles of Bladder Cancer Surgery. **2014**, 5-25 1
- 165 Bladder Cancer. **2014**, 289-308 1
- 164 Clinical Scenario: The Role of Perioperative Chemotherapy. **2015**, 441-447

- 163 Management of Bladder Cancer, Role of Chemotherapy and Controversies Surrounding Its Application. **2015**, 387-403
- 162 Management of Pelvic Retroperitoneal Tumors. **2015**, 209-216
- 161 Urothelcelcarcinoom. **2015**, 115-126
- 160 Muscle-invasive transitional cell carcinoma of the bladder. **2015**, 133-142
- 159 Perioperative chemotherapy for muscle-invasive urothelial carcinoma of the bladder. **2015**, 142-156
- 158 Neoadjuvant accelerated MVAC therapy in bladder cancer: toxicity and efficacy correlation. **2015**, 3, 582-594
- 157 Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder. **2016**, 8, 131-5
- 156 Urologic Oncology. **2016**, 77-107
- 155 Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice. **2016**, 10, 31-2 1
- 154 Current position of chemotherapy in treating bladder cancer. **2016**, 17, 64-68
- 153 Systemic treatment for bladder cancer. **2016**, 17, 102-105 1
- 152 Harnblasenkarzinom beim alten und geriatrischen Patienten. **2017**, 1-12
- 151 Neoadjuvant chemotherapy for muscle-invasive bladder cancer. **2017**, 18, 162-164
- 150 Risk Stratification and Prognostication of Bladder Cancer. **2018**, 1-14
- 149 Peri-operative Chemotherapy for Muscle-Invasive Bladder Cancer. **2018**, 1-19
- 148 Local Treatment, Radical Cystectomy, and Urinary Diversion. **2018**, 1-21
- 147 Is There Still a Role for Radical Cystectomy?. **2018**, 55-64
- 146 Neoadjuvant Chemotherapy in Muscle Invasive Urothelial Bladder Cancer. **2018**, 241-248

- 145 Harnblasenkarzinom beim alten und geriatrischen Patienten. **2018**, 461-472
- 144 Robotic radical cystectomy for the management of bladder cancer: Analysis of operative and pathological outcomes of eighteen patient. **2018**, 44, 311-315 1
- 143 Combined bladder-saving procedures in the treatment of locally advanced urothelial tumors. **2018**, 19, 121-125
- 142 Trends in the use of neoadjuvant chemotherapy for bladder cancer with nonurothelial variant histology: An analysis of the National Cancer Database. **2019**, 35, 291-298 1
- 141 Genitourinary Cancers. **2019**, 313-359
- 140 Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study. **2019**, 72, 100-105 2
- 139 Chemotherapy and targeted therapy for bladder cancer. **2019**, 13, 201-204
- 138 Bladder Cancer. **2020**, 561-578
- 137 Self-Assembled Nanoparticle-Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition. **2020**, 3, 2000032 4
- 136 Editorial comment: the effect of neoadjuvant chemotherapy on tumour downstaging and outcomes in patients with muscle invasive bladder cancers. **2020**, 9, 977-980
- 135 Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYC trial. **2021**, 21, 1161 0
- 134 Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013. **2021**,
- 133 Near Infrared Fluorescence Applications in Urinary Bladder Cancer. **2020**, 203-211
- 132 Trimodal therapy in muscle invasive bladder cancer management. **2020**, 72, 650-662 3
- 131 Etiology of Treatment Delays in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. **2020**, 6, 435-444
- 130 Time to change the management of upper urinary tract urothelial carcinoma. **2020**, 73, 381-382
- 129 Malignant diseases of the urinary tract. **2020**, 5136-5149
- 128 Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer. *European Urology*, **2021**, 81, 62-62 10.2

127	The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review.. 2022 , 20, 1-13		3
126	Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience. 2020 , 9, 121-125		0
125	Harnblasenkarzinom. 2014 , 415-502		0
124	Concomitant Radiation and Chemotherapy in Muscle-Invasive Bladder Cancer. 2006 , 285-302		
123	What happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy?. 2009 , 25, 282-3		1
122	Targeted therapies in the management of metastatic bladder cancer. 2007 , 1, 393-406		7
121	Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. 2012 , 6, E217-23		8
120	Outcome of urinary bladder cancer after combined therapies. 2016 , 9, 153-9		10
119	Outcome of urinary bladder cancer after combined therapies. 2016 , 9, 95-100		10
118	Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4. 2017 , 7, 2209-2219		40
117	Management of Advanced Bladder Cancer: An Update. 2018 , 9, 410-416		7
116	Mutations of predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. 2021 , 7, 386-413		1
115	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis. 2021 , 73, 572-580		3
114	A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019. 2021 , 1-5		0
113	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 40, 106.e11-106.e11	2.8	1
112	A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer. 2021 , 1-7		1
111	Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives. 2021 ,		0
110	BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP. 2021 ,		11

109	Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. <i>European Urology</i> , 2021 , 81, 50-50	10.2	4
108	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. 2021 ,		0
107	Immunotherapy for non-muscle-invasive bladder cancer: from the origins of BCG to novel therapies. 2022 , 18, 105-115		0
106	Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. <i>European Urology</i> , 2021 ,	10.2	7
105	Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review. 2021 , 11,		2
104	Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?. 2021 , 73, 674-676		
103	Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial). 2021 , 21, 1292		3
102	Urothelkarzinom der Harnblase: Neoadjuvante und adjuvante medikamentöse Tumorthherapie. 2021 , 1-5		
101	Landscape of Immunotherapy in Genitourinary Malignancies.. 2021 , 1342, 143-192		0
100	Ongoing Trial and Clinical Trial Endpoint Debate: The Role of Pathologic Response as a Surrogate of Survival Endpoints. 2022 , 75-89		
99	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.. 2022 , 207, 302-313		0
98	Neoadjuvant chemotherapy for upper tract urothelial carcinoma.. 2020 , 9, 6576-6582		0
97	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. 2021 ,		2
96	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101485 ^{2.2}		2
95	Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study.. 2022 , 1		0
94	Systemtherapien beim Urothelkarzinom der Harnblase und des oberen Harntrakts. 2022 , 24, 18-21		
93	Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database.. 2022 ,		0
92	Clinical Case Debate: Neoadjuvant Checkpoint Inhibition Versus Standard Chemotherapy. 2022 , 13-25		

91	Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer. 2022 , 381-424		
90	Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer. 2022 , 349-379		
89	Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.. 2022 , 23,		5
88	Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.. <i>International Journal of Urology</i> , 2021 ,	2.3	0
87	Biomarkers in muscle invasive bladder cancer.. 2022 , 107, 265-297		0
86	A PROSPECTIVE COMPARATIVE STUDY ON MUSCLE INVASIVE BLADDER CANCER TREATED WITH BLADDER PRESERVATION APPROACH USING NEOADJUVANT CHEMOTHERAPY FOLLOWED BY RADIOTHERAPY VERSUS CONCURRENT CHEMORADIATION. 2022 , 12-15		
85	Methods of Sentinel Lymph Node Detection and Management in Urinary Bladder Cancer-A Narrative Review.. 2022 , 29, 1335-1348		2
84	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102051	2.2	8
83	PARP inhibitors chemopotentiates and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.. 2022 , 22, 312		0
82	Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.. 2022 , 2022, 8493519		
81	SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).. 2022 , 24, 613		1
80	Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen. 2022 , 8, 71-80		1
79	Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging.. 2022 , 1		
78	Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.. 2022 , 7, 100416		1
77	Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group.. 2021 , 28, 5084-5100		0
76	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review.. 2021 , 14,		3
75	Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications.. 2021 , 13,		0
74	Non-surgical treatment of bladder cancer. 2020 , 21, 102-106		

73	Photo-Enhanced Chemotherapy Performance in Bladder Cancer Treatment via Albumin Coated AIE Aggregates.. <i>ACS Nano</i> , 2022 ,	16.7	4
72	Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103683	7	0
71	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	0
70	Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands.. <i>World Journal of Urology</i> , 2022 , 1	4	
69	Data_Sheet_1.docx. 2018 ,		
68	A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.. <i>Molecular Cancer Therapeutics</i> , 2022 ,	6.1	1
67	Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.. <i>PLoS ONE</i> , 2022 , 17, e0267410	3.7	1
66	Geography Should Not Be an "Oncologic Destiny" for Urothelial Cancer: Improving Access to Care by Removing Local, Regional, and International Barriers.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-14	7.1	
65	Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2022 , 12,	5.3	0
64	Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis.. <i>Clinical Oncology</i> , 2022 ,	2.8	0
63	Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. <i>Advances in Oncology</i> , 2022 , 2, 213-225		
62	Bladder Cancer. 2022 , 51-65		0
61	Update on How to Improve the Outcome of Radical Cystectomy: A Systematic Review. <i>Annals of Urologic Oncology</i> , 2022 ,	0.1	
60	Update on How to Improve the Outcome of Radical Cystectomy: A Systematic Review. <i>Annals of Urologic Oncology</i> , 2022 ,	0.1	
59	Renal and urinary bladder cancer. 2023 , 327-335		
58	Reply to S. Zeng et al. <i>Journal of Clinical Oncology</i> ,	2.2	1
57	Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer when treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy. <i>Urology</i> , 2022 ,	1.6	
56	The effect of retroperitonealization of ureteroileal anastomosis on perioperative complications of radical cystectomy with ileal conduit urinary diversion. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022 , 94, 150-154	1.6	

55	Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy. <i>European Urology Oncology</i> , 2022 ,	6.7	
54	Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 ,	2.8	
53	The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 ,	2.8	○
52	Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy. <i>International Journal of Urology</i> ,	2.3	○
51	Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade. 2022 , 2022, 1-21		
50	Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments. 12,		○
49	Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021). 2022 , 18, 142-163		
48	Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.		
47	Stratégie de préservation vésicale basée sur le traitement trimodal: quelle place dans la prise en charge du carcinome infiltrant de la vessie?. 2022 ,		
46	Immune status for monitoring and treatment of bladder cancer. 13,		○
45	Predictive Biomarkers in the Management of Bladder Cancer: Perspectives in an Evolving Therapeutic Landscape. 2022 , 3, 245-257		○
44	Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer.		○
43	Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). 2022 , 14, 5286		○
42	Decision regret related to urinary diversion choices after cystectomy among Chinese bladder cancer patients.		○
41	Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis. 2022 , 14, 4841		1
40	Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. Volume 15, 1259-1269		○
39	Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.		○
38	Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3/4 or cN+ bladder cancer.		○

- 37 Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans. **2022**, 5, e2237699 ○
- 36 A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study. 13, ○
- 35 Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer. **2022**, 13, 1188-1200 ○
- 34 Burgery only reicht nicht aus: Potenziale einer multimodalen Therapie beim Urothelkarzinom der Harnblase. ○
- 33 Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review. **2022**, 14, 5644 ○
- 32 Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy. 12, ○
- 31 Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology. **2023**, 33, 62-69 ○
- 30 Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer. **2023**, 33, 35-50 ○
- 29 The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer. **2023**, 33, 51-55 ○
- 28 Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer. **2023**, 33, 56-61 ○
- 27 Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: A 20-year experience. **2022**, ○
- 26 Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review. **2022**, 14, 1407-1417 ○
- 25 Comparative effectiveness of radiation versus radical cystectomy for localized muscle-invasive bladder cancer. **2022**, 101157 ○
- 24 UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice [from biobank to RNA-sequencing in real time. 1-8 ○
- 23 A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer. **2022**, ○
- 22 Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study. **2022**, 22, ○
- 21 Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. ○
- 20 Health-related quality of life after curative treatment for muscle-invasive bladder cancer. ○

19	Immunotherapy for Urothelial Carcinoma. 2023 , 1-12	0
18	Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?. 2023 , 59, 50	1
17	Contemporary Systemic Therapies in Urothelial Carcinoma. 2023 ,	0
16	Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy. 2023 ,	0
15	Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis. 2022 , 18, 1884	0
14	High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. 2023 , 29, 588-592	0
13	Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy. 2023 , 41, 207.e1-207.e7	0
12	Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review. 2023 , 12, 1560	0
11	Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations. 2023 , 15, 1323	0
10	Do perioperative blood transfusions impact oncological outcomes of robot-assisted radical cystectomy with intracorporeal urinary diversion? Results from a large multi-institutional registry. 2023 , 75,	0
9	Perioperative Systemtherapie des Urothelkarzinoms. 2023 , 62, 407-417	0
8	Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study. 2023 , 13, 1032	0
7	Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. 2023 , 26, 411-421	0
6	Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. 2023 , 15, 1742	0
5	Predictive Value of 18F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer. Publish Ahead of Print,	0
4	Identifying novel biomarkers associated with bladder cancer treatment outcomes. 13,	0
3	PET Imaging in Bladder Cancer: An Update and Future Direction. 2023 , 16, 606	0
2	Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. 2023 ,	0

- 1 Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies. **2023**, 64, 202

o